KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Moderna (MRNA) EBITDA Margin (2017 - 2025)

Moderna (MRNA) has disclosed EBITDA Margin for 9 consecutive years, with 126.4% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 1972.0% to 126.4% in Q4 2025 year-over-year; TTM through Dec 2025 was 158.13%, a 4117.0% decrease, with the full-year FY2025 number at 158.13%, down 3622.0% from a year prior.
  • EBITDA Margin was 126.4% for Q4 2025 at Moderna, down from 25.59% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 75.02% in Q4 2021 to a low of 972.22% in Q1 2025.
  • A 5-year average of 180.43% and a median of 11.71% in 2024 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: surged 170286bps in 2021, then plummeted -73843bps in 2024.
  • Moderna's EBITDA Margin stood at 75.02% in 2021, then tumbled by -59bps to 31.08% in 2022, then tumbled by -99bps to 0.21% in 2023, then tumbled by -50079bps to 106.68% in 2024, then dropped by -18bps to 126.4% in 2025.
  • Per Business Quant, the three most recent readings for MRNA's EBITDA Margin are 126.4% (Q4 2025), 25.59% (Q3 2025), and 638.73% (Q2 2025).